Using ddPCR, researchers discover expression levels of seven key biomarkers in the bone marrow samples of 17 patients who had suffered tumor relapse and regrowth were significantly higher compared to the levels in the 56 patients who hadn't relapsed.
The study presents clinical evidence for an innovative liquid biopsy assay which can detect cell clusters of any type of cancer called C-ETACs (Circulating Ensembles of Tumor Associated Cells) in the blood of asymptomatic individuals.
Companies plan to combine ProSciento’s NASH PASS patient registry with Nordic Bioscience’s Protein FingerPrint technology.
Although CTCs can be detected in melanoma patients, there is limited data regarding their significance in stage III (node-positive) disease. This prospective study was based on earlier studies that found CTCs in a significant number of breast cancer patients was associated with relapse, independent of other prognostic methods.
Biological Dynamics is developing assays for pharmaceutical applications built on Verita, the company’s proprietary biomarker isolation technology that can isolate DNA and extracellular vesicles from plasma and serum without the need to pre-process samples.
The research team correlated the genetic and protein fingerprints of brain cancer cells with how those cells and surrounding cells looked using MRI, a test routinely performed as soon as brain cancer is suspected.
The researchers performed deep sequencing of both circulating cfDNA and of white blood cells to look for mutations. Subtracting the white blood cells’ information from cfDNA yielded data investigators could use to predict cancer recurrence within nine weeks following preoperative treatment and surgery.
The researchers developed an algorithm that was able to detect how patients’ gene expression patterns changed over decades, offering the first long-term view of molecular changes underlying neurodegeneration.
The Clinical Genome Resource's (ClinGen) expert panel has critically reevaluated the scientific evidence for all 17 reported genes, and has concluded at least nine of the genes cannot be linked to the disease, and only three of the genes can be definitively associated with the most common form of the disease.
The program’s goal is to identify hereditary diseases that might cause a child’s seizures. Participating companies sponsor the cost of testing using the Invitae Epilepsy Panel, which analyzes more than 180 genes associated with causes of epilepsy and other neurodegenerative conditions.